结构性心脏病经导管介入治疗患者的抗栓治疗
本综述汇总了主动脉瓣植入、二尖瓣或三尖瓣修复/植入、左心耳封堵及卵圆孔未闭封堵等经导管结构性心脏介入术前、术中、术后抗栓治疗的现有证据,指出各术式在血栓栓塞与出血风险平衡上仍存争议,最佳抗栓方案尚不明确,强调需个体化制定抗栓策略。
要点
- 经导管结构性心脏介入围术期需抗栓治疗以预防血栓栓塞,但增加出血风险。
- 不同术式(TAVI、二尖瓣/三尖瓣介入、LAAO、PFO封堵)的抗栓方案存在差异与争议。
- 目前各特定术式的最佳抗栓方案尚不明确,应强调个体化 tailored 策略。
核心结论
- 经导管结构性心脏介入患者抗栓治疗需在血栓栓塞与出血风险间平衡,最佳方案尚不明确,强调个体化策略。
研究设计与样本
- 综述,总结经导管结构性心脏介入抗栓治疗的当前证据。
主要发现
- 经导管结构性心脏介入术前、术中或术后需抗栓治疗以预防血栓栓塞事件,但抗栓治疗与出血并发症风险增加相关。
- 主动脉瓣植入、二尖瓣或三尖瓣修复/植入、左心耳封堵及卵圆孔未闭封堵在临床适应证和操作方面存在显著差异。
- 各特定术式的最佳抗栓方案仍不明确,血栓与出血风险平衡存在挑战和争议。
临床怎么用
- 临床应针对具体经导管结构性心脏介入术式,个体化权衡血栓栓塞与出血风险制定抗栓方案。
局限性
- 各特定术式的最佳抗栓方案尚不明确,现有证据存在挑战与争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Contemporary evidence supports device-based transcatheter interventions for the management of patients with structural heart disease. These procedures, which include aortic valve implantation, mitral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with respect to clinical indications and procedural aspects. Yet, patients undergoing transcatheter cardiac interventions require antithrombotic therapy before, during, or after the procedure to prevent thromboembolic events. However, these therapies are associated with an increased risk of bleeding complications. To date, challenges and controversies exist regarding balancing the risk of thrombotic and bleeding complications in these patients such that the optimal antithrombotic regimens to adopt in each specific procedure is still unclear. In this review, we summarize current evidence on antithrombotic therapies for device-based transcatheter interventions targeting structural heart disease and emphasize the importance of a tailored approach in these patients.
引用
- Calabrò P, Gragnano F, Niccoli G, et al. Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. Circulation. 2021. PMID: 34662163. doi:10.1161/CIRCULATIONAHA.121.054305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。